Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/jac/dkz218 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Letermovir-inclusive combination therapy for a refractory and resistant infection by cytomegalovirus with UL54 mutation following a hematopoietic stem cell transplant for MHC Class II deficiency.
J Infect Chemother
January 2025
Division of Infectious Diseases, Department of Pediatrics, Tokyo Metropolitan Children's Medical Center, Tokyo, Japan; Division of Immunology, Department of Pediatrics, Tokyo Metropolitan Children's Medical Center, Tokyo, Japan.
Cytomegalovirus (CMV) infection remains one of the most common and challenging post-transplant infections. Children with inborn errors of immunity (IEI) and T-cell dysfunction are at high risk for CMV infection, which can be complicated by refractory and/or resistant cases. This case describes a Nepalese girl with MHC class II deficiency, who presented at 3 months of age with CMV and Pneumocystis jirovecii pneumonia.
View Article and Find Full Text PDFPre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients.
Cochrane Database Syst Rev
January 2025
Cochrane Kidney and Transplant, Centre for Kidney Research, The Children's Hospital at Westmead, Westmead, Australia.
Background: Cytomegalovirus (CMV) is a significant cause of morbidity and death in solid organ transplant recipients. Pre-emptive treatment of patients with CMV viraemia using antiviral agents has been suggested as an alternative to routine prophylaxis to prevent CMV disease. This is an update of a Cochrane review first published in 2006 and updated in 2013.
View Article and Find Full Text PDFLetermovir prophylaxis for cytomegalovirus in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation.
Bone Marrow Transplant
January 2025
Department of Hematology and Oncology, Children's Hospital of Soochow University, Suzhou, China.
CMV-Related Hemorrhagic Retinal Vasculitis in a Multiple Myeloma Patient on Daratumumab Therapy: A Case Report.
Ocul Immunol Inflamm
November 2024
Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Ontario, Canada.
Purpose: To report a case of cytomegalovirus (CMV)-related hemorrhagic retinal vasculitis in a patient with multiple myeloma (MM) on daratumumab, a trial cereblon E3 ligase modulatory drug (CELMoD), dexamethasone, and acyclovir, and discuss clinical implications for CMV prophylaxis.
Methods: Case report, narrative review of CMV reactivation risk in MM patients on daratumumab and antiviral agent efficacy for CMV prophylaxis.
Results: A 63-year-old female presented with 3 days of progressive unilateral vision loss in the right eye to the level of counting fingers.
Letermovir at a Prophylactic Dose for Cytomegalovirus Infection in Children Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Center Retrospective Study in Japan.
Biol Pharm Bull
September 2024
Department of Pharmacy, Okayama University Hospital.
Article Synopsis
- Cytomegalovirus (CMV) infection is a significant risk after hematopoietic stem cell transplantation (HSCT) in children, and this study investigates the effects of letermovir, a prophylactic treatment, on CMV infections following HSCT.
- A retrospective analysis of 79 pediatric patients showed that while the overall incidence of CMV infection was not significantly different between those who received letermovir and those who did not, letermovir was associated with a lower incidence of CMV infection in the first 100 days post-transplant.
- Despite minimal side effects, such as nausea in one case, the findings suggest that letermovir could be an effective preventive measure against CMV in children undergoing HSCT.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!